ProBioGen and Pionyr Immunotherapeutics initiate second collaboration

Collaboration in contract development and manufacturing

11-Jul-2018 - ProBioGen AG, a premier service and technology provider for complex therapeutic glycoproteins, andPionyr Immunotherapeutics, an immuno-oncology company which develops next generation antibody-based therapeutics that target the tumor microenvironment, today announced a second service and license ...

Boehringer Ingelheim Licenses ProBioGen's Novel GlymaxX Technology

12-Aug-2011 - Boehringer Ingelheim and ProBioGen AG announced that they have signed a non-exclusive Licensing Agreement regarding ProBioGen’s GlymaxX® technology. Boehringer Ingelheim’s Contract Manufacturing Business will apply the technology to enhance ADCC (Antibody-Dependent Cell-Mediated Cytotoxicity) ...

Minapharm Pharmaceuticals Acquires Majority Stake in ProBioGen

Dr. Wieland Wolf Appointed New CEO

18-Jun-2010 - ProBioGen AG announced that Minapharm Pharmaceuticals, Cairo, has completed the acquisition of 95% of the share capital of ProBioGen, an internationally renowned German cell line development and contract manufacturing specialist. The total purchase price of EUR 30.4 million includes earn-out ...

Probiogen Signs Therapeutic Protein Process Development Contract With Virdante Pharmaceuticals

30-Apr-2010 - ProBioGen AG announced signing a contract with Virdante Biopharmaceuticals, Inc., a US-based biopharmaceutical development company. ProBioGen will contribute producer cell line development and process engineering for one of Virdante’s proprietary therapeutic proteins. Virdante’s protein ...

Patent granted for ProBioGen's avian cell line AGE1.CR

14-Jul-2008 - ProBioGen AG, a biotechnology company in cell engineering and production of biopharmaceuticals, has been granted patent protection for AGE1.CR, a proprietary duck cell line developed for the production of human and animal vaccines and proteins. The granted patent as parent, ProBioGen also claims ...

ProBioGen and Boehringer Ingelheim enter into Strategic Production Alliance

02-May-2008 - ProBioGen AG announced a strategic production agreement with Boehringer Ingelheim. Under the agreement, ProBioGen will integrate some of Boehringer Ingelheim´s technologies to accommodate a seamless process and technology transfer from pilot and medium-scale to commercial-scale production ...

ProBioGen Announces Exclusive Licensing Agreement for its Proprietary Avian Cell Line AGE1.CR

Significant upfront and milestone payments plus royalties for four indications

10-Dec-2007 - ProBioGen AG announced the closing of an exclusive licensing agreement for its avian cell line AGE1.CR. The agreement was signed with an undisclosed US vaccine development company and covers a total of four indications, including different forms of influenza and three additional disease ...

Dr Gertraud Unterrainer Joins ProBioGen as Chief Financial Officer

11-Oct-2007 - ProBioGen AG announced the appointment of Dr Gertraud Unterrainer to Chief Financial Officer. Dr Unterrainer will complement and strengthen ProBioGen's current management team consisting of Michael Schlenk, CEO, and Dr Uwe Marx, CSO. Dr Unterrainer previously served as Chief Financial Officer of ...

ProBioGen reinforces its Business Development Team

31-Aug-2007 - ProBioGen AG announced that Dr Klaus Stünkel will take over the position of Vice President Business Development Licensing with immediate effect. Mr Stünkel brings with him experience gathered over many years in the areas of Business Development (including 15 years in licensing) and R&D at Bayer ...

ProBioGen and Minapharm Enter into Development and Co-promotion Agreements

24-Apr-2007 - ProBioGen and Minapharm jointly announced that they have entered into two separate agreements to develop two therapeutic proteins, one exclusively for Minapharm and another second generation biopharmaceutical product for co-promotion. In the first agreement, ProBioGen will apply its cell ...